Mission & Values
Our Mission
Our Service
To provide access to infusion therapy clinical services in a non-institutional, friendly environment, while operating under the highest standards and observing the Canada Health Act and other regulations of the medical profession that may apply.
For our Patients
To respect the privacy and individuality of all our patients, while protecting their interests, honouring their trust, exceeding their expectations and offering all of our expertise in the interest of their well-being.
For our Employees
To provide a working environment that supports the professional goals and respects the personal values of each individual; to value their loyalty, respect their skills and provide equal opportunity to all.
For the Community
To be a good corporate citizen by donating time and funds to worthy efforts and to encourage our employees to be involved in their community to serve our society and environment.
Our Vision
We will be the leader in providing infusion therapy services in Canada. We will strive to earn the confidence of our patients and their families and the respect of the medical community by providing the highest standards of care. We will continuously apply our best efforts to provide and develop additional modalities that will assist patients in gaining access to health care services while respecting the Canada Health Act.
Why Choose Provis?
- Infusion Services Since 2005
- Over 13,000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
15 Year Anniversary!
The Provis Infusion Clinic is please to announce that August 2020 marks the 15 anniversary of the Provis Infusion Clinic. We are looking forward to the next 15 years of providing high quality infusion services.COVID 19 Trial
Provis is pleased to partner with University Health Network, University of Toronto, EMS services and Police Services on a Phase 3 Clinical Trial focusing on COVUD 19. Called 'Cobra' the trial will look at the effectiveness of the vaccine BCG in the minimization of the COVID symptoms and the contraction of the virus.New Medications
Venofer™ (Iron Sucrose) Onivyde™ (Irinotecan liposome for injection) Tecentriq™ (Atezolizumab) Renflexis™ (Infliximab) Yondelis™ (Trabectedin) Yervoy™ (Ipilimumab)Kyprolis™ (Carfilzomib) receives Health Canada approval.
Health Canada has approved Kyprolis™ (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.Opdivo™ (Nivolumab) receives Health Canada approval.
Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.Keytruda™ (Pembrolizumab) now offered at Provis
AUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitorUpdate – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane® Kadcyla® Tecentriq® Yervoy® Opdivo® Patients: Provis participates in the Roche Patient Assistance Program, the , the OnCare Program, the Merck Care Oncology, and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Tecentriq®, Keytruda®, Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Opdivo® ® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder Cancer
Provis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.